Atea Pharmaceuticals, Inc. (AVIR) Institutional Ownership

Ownership Summary

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) has 109 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 72.0% of Atea Pharmaceuticals's outstanding shares in December 2025, up from 68.4% in September 2025.
• Their total shares held in AVIR increased 7.1% quarter over quarter, and separately, investors owning Atea Pharmaceuticals increased 0.93% from a year ago.
• Of these 109 funds, 43 grew their exposure to Atea Pharmaceuticals, 41 cut back, and 25 maintained positions.
• The aggregate institutional position in Atea Pharmaceuticals amounted to 56.93Mn shares as of December 2025, up by 3.77Mn shares quarter on quarter, and down 161.05K shares year over year.
• FMR LLC leads ownership in AVIR with 11.95Mn shares as of December 31, 2025, equal to 15.12% of outstanding shares.
• The most significant purchases of AVIR for the quarter ending December 2025 came from VANGUARD CAPITAL MANAGEMENT LLC (3.25Mn), FMR LLC (2.27Mn), Rosalind Advisors, Inc. (1.17Mn), TWO SIGMA INVESTMENTS, LP (1.12Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (557.58K).
• Leading sellers of Atea Pharmaceuticals shares for the quarter ending December 2025 were BML Capital Management, LLC (431.34K), Jpmorgan Chase & Co (408.14K), Goldman Sachs Group Inc (356.58K), MILLENNIUM MANAGEMENT LLC (348.22K), HSBC HOLDINGS PLC (223.56K).
• Per Business Quant, the top 10 investors in AVIR for the quarter ending December 2025 include FMR LLC (11.95Mn), BlackRock, Inc. (8.44Mn), BML Capital Management, LLC (7.06Mn), TANG CAPITAL MANAGEMENT LLC (4.81Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.25Mn), Bain Capital Life Sciences Investors, LLC (2.36Mn), TWO SIGMA INVESTMENTS, LP (1.86Mn), GEODE CAPITAL MANAGEMENT, LLC (1.75Mn), State Street Corp (1.69Mn), ACADIAN ASSET MANAGEMENT LLC (1.58Mn).